How large is the new share repurchase program and how will it be funded?

The board authorized repurchases of up to $1.5 billion of Roivant common shares (excluding fees and expenses). The program will be funded with available cash and cash equivalents on hand and has no expiration date. Purchases may be made through open market transactions, tender offers, or privately negotiated transactions, including Rule 10b5-1 trading plans.

What is the Sumitomo Pharma share repurchase?

Roivant entered into a share repurchase agreement on April 2, 2024 to buy all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. at $9.10 per share, for an aggregate price of approximately $648.4 million. The transaction is expected to close on or about April 4, 2024, and the company states it will reduce shares outstanding by approximately 9%.

What did the NEPTUNE study show for brepocitinib in non-infectious uveitis?

At week 24, the primary Treatment Failure rate was 29% (5 of 17) in the 45 mg arm and 44% (4 of 9) in the 15 mg arm; lower rates indicate greater benefit. The study enrolled 26 subjects randomized 2:1, and all secondary endpoints were reported as positive and dose responsive. The press release states that the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this endpoint.

What are the next clinical milestones for brepocitinib?

Priovant intends to initiate a Phase 3 program in non-infectious uveitis in the second half of calendar year 2024. The ongoing Phase 3 dermatomyositis study is expected to be fully enrolled in the third calendar quarter of 2024, with data expected in calendar year 2025. Additional safety and efficacy data will be presented at a future medical conference.

Are there any limits or uncertainties around the repurchase program?

The filing states that the program may be suspended or discontinued at any time, and there can be no assurance as to how many additional common shares will be repurchased or at what prices. The timing and amount of repurchases depend on factors including the market price of the shares, general business, macroeconomic and market conditions, and other investment opportunities.

ROIV 8-K SEC Disclosure

01—Abstract

Summary

Summary of the 8-K filed April 2, 2024. Cited figures are marked; the original filing is the authoritative source.

Roivant Sciences Ltd. (ROIV) reported on April 2, 2024, in a Form 8-K (Item 8.01) that it announced positive results from the Phase 2 NEPTUNE study of brepocitinib in non-anterior non-infectious uveitis (NIU), and that its board authorized a share repurchase program of up to $1.5 billion^a of common shares, funded with available cash and cash equivalents and without an expiration date.

As part of this program, Roivant entered into an agreement to repurchase all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. at $9.10^b per share, for an aggregate of approximately $648.4 million, with closing expected on or about April 4, 2024. The company states this repurchase will reduce shares outstanding as of February 9, 2024 by approximately 9%. On the clinical side, the press release states that at week 24, 29% (5 of 17) of subjects in the brepocitinib 45 mg arm and 44% (4 of 9) in the 15 mg arm met the primary Treatment Failure endpoint, with lower rates indicating greater benefit.

The Treatment Failure rate from disease activity (discontinuations censored) was 18%^c in the 45 mg arm. All secondary endpoints were reported as positive and dose responsive, and no new safety or tolerability signals were identified. The study enrolled 26 subjects, and the company plans to begin a Phase 3 NIU program in the second half of calendar year 2024, while the ongoing Phase 3 dermatomyositis study is expected to read out in calendar year 2025.

The filing also indicates that the repurchase program may be suspended or discontinued at any time, and that there can be no assurance of how many shares will be repurchased or at what prices. Roivant plans an investor call and webcast at 8:00 a.m. EDT on April 2, 2024 to discuss the results and the repurchase program.

02—Key points

Key Highlights

Board authorized a share repurchase program of up to $1.5 billion of common shares, with no expiration date and funded from cash and cash equivalents on hand.
Roivant agreed to repurchase all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. at $9.10 per share, for approximately $648.4 million, expected to close on or about April 4, 2024.
The Sumitomo Pharma repurchase is stated to reduce shares outstanding as of February 9, 2024 by approximately 9%.
Phase 2 NEPTUNE study: 29% of subjects on brepocitinib 45 mg (5/17) and 44% on 15 mg (4/9) met the primary Treatment Failure endpoint at week 24; the 45 mg Treatment Failure rate from disease activity (discontinuations censored) was 18%.
All week 24 secondary efficacy endpoints were positive and dose responsive, including haze grades, visual acuity, and macular thickness; 43% of 45 mg patients with baseline uveitic macular edema achieved resolution by week 24.
Brepocitinib was generally safe and well tolerated in NEPTUNE, with no new safety or tolerability signals identified; the drug has been dosed in over 1,400 subjects and patients.
Priovant plans to initiate a Phase 3 NIU program in the second half of calendar year 2024, and the Phase 3 dermatomyositis study is expected to read out in calendar year 2025.

03—Questions

Frequently Asked Questions

How large is the new share repurchase program and how will it be funded?
The board authorized repurchases of up to $1.5 billion of Roivant common shares (excluding fees and expenses). The program will be funded with available cash and cash equivalents on hand and has no expiration date. Purchases may be made through open market transactions, tender offers, or privately negotiated transactions, including Rule 10b5-1 trading plans.
What is the Sumitomo Pharma share repurchase?
Roivant entered into a share repurchase agreement on April 2, 2024 to buy all 71,251,083 common shares held by Sumitomo Pharma Co., Ltd. at $9.10 per share, for an aggregate price of approximately $648.4 million. The transaction is expected to close on or about April 4, 2024, and the company states it will reduce shares outstanding by approximately 9%.
What did the NEPTUNE study show for brepocitinib in non-infectious uveitis?
At week 24, the primary Treatment Failure rate was 29% (5 of 17) in the 45 mg arm and 44% (4 of 9) in the 15 mg arm; lower rates indicate greater benefit. The study enrolled 26 subjects randomized 2:1, and all secondary endpoints were reported as positive and dose responsive. The press release states that the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this endpoint.
What are the next clinical milestones for brepocitinib?
Priovant intends to initiate a Phase 3 program in non-infectious uveitis in the second half of calendar year 2024. The ongoing Phase 3 dermatomyositis study is expected to be fully enrolled in the third calendar quarter of 2024, with data expected in calendar year 2025. Additional safety and efficacy data will be presented at a future medical conference.
Are there any limits or uncertainties around the repurchase program?
The filing states that the program may be suspended or discontinued at any time, and there can be no assurance as to how many additional common shares will be repurchased or at what prices. The timing and amount of repurchases depend on factors including the market price of the shares, general business, macroeconomic and market conditions, and other investment opportunities.

04—Continue

← View all 8-K filings